An Innovative View of Moderate-to-Severe Atopic Dermatitis: Stepping Up Care with Systemic Therapies
March 30, 2023
March 30, 2024
This activity is provided by Med Learning Group.
This program is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
- Physicians — maximum of .5 AMA PRA Category 1 Credit(s)™
- Nurses — .5 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is intended for dermatologists, allergists, primary care physicians, pediatricians, and other healthcare professionals involved in the management of pediatric and adult patients with moderate-to-severe atopic dermatitis (AD).
This program uses a unique, interactive approach to providing the most up to date information on the use of systemic therapies and multidisciplinary care in atopic dermatitis.
After participating in this program, participants will be better able to:
- Diagnose AD and assess patients for disease severity and quality of life issues
- Personalize the selection of systemic therapies based on disease severity, quality of life, and other patient-specific factors
- Utilize guideline recommendations and clinical trial data to develop treatment plans for disease exacerbations and long-term management of AD in pediatric and adult patients
Peter A. Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Med Learning Group designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of .5 ANCC contact hour.
Disclosures of Conflicts of Interest
- Peter A. Lio, MD
- Research Grants/Funding: AbbVie, AOBiome, Eczema Foundation, National Eczema Association
- Speaker's Bureau : AbbVie, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L’Oreal, MyOR Diagnostics, ParentMD, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme
- Reports Consulting/Advisory Boards : AbbVie, Almirall, Amyris, Arbonne, ASLAN, Bodewell, Boston Skin Science, Bristol-Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosci, Dermavant, Dermira, DermVeda, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosci, Kimberly Clark, LEO Pharma, Lipidor, L’Oreal, Menlo Therapeutics, Merck, Micreos, MyOR Diagnostics, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Sonica, Theraplex, UCB, Unilever, Verrica, Yobee Care
- Stock Options: LearnSkin/Learn Health, Medable, Micreos, Modernizing Medicine, Yobee Care
- Patent Pending: Theraplex
- Royalties/Board Member/Scientific Advisory Committee Member: National Eczema Association
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact: [email protected]
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]